Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 4/20 | 0.44 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 10/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 9/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 7/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.41 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.34 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.34 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 3/20 | 0.33 |
| ▸ | HTR3A | P46098 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL807516 | 0.81 | TLR9 (0.36) | SLC6A2SLC6A3SLC6A4CYP2D6KCNH2 | |
| SCHEMBL11981471 | 0.79 | CHRNB2 (0.47) | CHRNB2CHRNA4SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL21872210 | 0.76 | SLC6A2 (0.39) | SLC6A2SLC6A3SLC6A4CYP2D6KCNH2 | |
| SCHEMBL25262561 | 0.71 | SLC6A2 (0.68) | CHRNB2CHRNA4SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL21026523 | 0.71 | CHRNB2 (0.46) | CHRNB2CHRNA4SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL11981506 | 0.71 | SLC6A2 (0.35) | SLC6A2SLC6A3SLC6A4CYP2D6KCNH2 | |
| Hydrochloric Acid SCHEMBL25268867 | 0.69 | SLC6A2 (0.66) | CHRNB2CHRNA4SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL31168012 | 0.68 | CHRNB2 (0.43) | CHRNB2CHRNA4SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL27042964 | 0.67 | CHRNB2 (0.31) | CHRNB2CHRNA4 | |
| SCHEMBL21872041 | 0.66 | APP (0.36) | SLC6A2SLC6A3SLC6A4CYP2D6KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140171408-A1 | AZABENZOTHIAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | GENENTECH, INC. (US) | 2014-06-19 | — | — | US | disclosed |
| US-20120202788-A1 | AZABENZOTHIAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2012-08-09 | — | — | US | disclosed |
| US-20120202788-A1 | AZABENZOTHIAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2012-08-09 | — | — | US | disclosed |
| WO-2012035039-A1 | AZABENZOTHIAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2012-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140171408-A1 | AZABENZOTHIAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | F12, CHRM1, NPY1R | CHRNB2 252/4885CHRNA4 440/4885SLC6A2 595/4885 |
| US-20120202788-A1 | AZABENZOTHIAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | F12, CHRM1, NPY1R | CHRNB2 252/4885CHRNA4 440/4885SLC6A2 595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.